The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential

Objective—To determine the role of Wnt antagonist Dickkopf (DKK) 1 in human endothelial colony-forming cells (ECFCs) in view of the emerging importance of Wnt pathways in vascular biology. Methods and Results—Endothelial progenitor cells have been proposed to be crucial in tumor neovascularization. Recombinant DKK1 has been tested in ECFC angiogenic properties in vitro. DKK1 enhanced ECFC proliferation and the capacity of ECFCs to form pseudotubes in Matrigel. These effects have been attributed to enhancement of vascular endothelial growth factor receptor 2, SDF-1, and CXCR4. DKK1 gene silencing has been realized on ECFCs and mesenchymal stem cells, and we found that DKK1 silencing in the 2 cell types decreased their angiogenic potential. We then examined the possible role of DKK1 in tumor neovasculogenesis and found that blood vessels of breast cancer tissues expressed DKK1 far more strongly in human breast tumors than in normal breast tissues. By studying 62 human breast tumors, we found a significant positive correlation between DKK1 expression and von Willebrand factor. In vivo, DKK1 strongly enhanced the vascularization of Matrigel plugs and increased tumor size in a xenograft model of human breast carcinoma in nude mice. Conclusion—DKK1 enhances angiogenic properties of ECFCs in vitro and is required for ECFC and mesenchymal stem cell angiogenic phenotypes in vivo. DKK1 also increases tumoral angiogenesis. Thus, we demonstrated a major role of DKK1 in angiogenic processes.

[1]  M. Lacey,et al.  Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence , 2010, Breast Cancer Research and Treatment.

[2]  I. Bièche,et al.  Interleukin 8 is differently expressed and modulated by PAR‐1 activation in early and late endothelial progenitor cells , 2009, Journal of cellular and molecular medicine.

[3]  N. Altorki,et al.  Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. , 2009, Biochimica et biophysica acta.

[4]  A. Gabrielsen,et al.  Dickkopf-1 Enhances Inflammatory Interaction Between Platelets and Endothelial Cells and Shows Increased Expression in Atherosclerosis , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[5]  M. Hermann,et al.  Dkk‐3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas , 2009, Cancer science.

[6]  M. Katoh,et al.  Transcriptional regulation of WNT2B based on the balance of Hedgehog, Notch, BMP and WNT signals. , 2009, International journal of oncology.

[7]  M. Rajan,et al.  Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast , 2009, Journal of Cancer Research and Clinical Oncology.

[8]  F. Journé,et al.  Assessment of Circulating Dickkopf-1 with a New Two-Site Immunoassay in Healthy Subjects and Women with Breast Cancer and Bone Metastases , 2009, Calcified Tissue International.

[9]  S. Germain,et al.  Bone Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[10]  T. Couffinhal,et al.  Secreted Frizzled‐Related Protein‐1 Enhances Mesenchymal Stem Cell Function in Angiogenesis and Contributes to Neovessel Maturation , 2008, Stem cells.

[11]  R. Rostomily,et al.  Dickkopf-1 mediated tumor suppression in human breast carcinoma cells , 2008, Breast Cancer Research and Treatment.

[12]  C. Heeschen,et al.  The Wnt Antagonist Dickkopf-1 Mobilizes Vasculogenic Progenitor Cells via Activation of the Bone Marrow Endosteal Stem Cell Niche , 2008, Circulation research.

[13]  Xiao-dong Zhang,et al.  Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. , 2008, Cancer letters.

[14]  Eric D. Adler,et al.  Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.

[15]  I. Bièche,et al.  Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells , 2008, Journal of cellular and molecular medicine.

[16]  R. Kerbel,et al.  Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation , 2007, PloS one.

[17]  N. Munshi,et al.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. , 2007, Blood.

[18]  L. Muller,et al.  Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin α6 , 2007, Journal of cellular and molecular medicine.

[19]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[20]  V. Korzh,et al.  The chemokine Sdf-1 and its receptor Cxcr4 are required for formation of muscle in zebrafish , 2007, BMC Developmental Biology.

[21]  J. Emmerich,et al.  Endothelial progenitor cells: Characterization, in vitro expansion, and prospects for autologous cell therapy , 2007, Cell Biology and Toxicology.

[22]  J. Prchal,et al.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. , 2007, Blood.

[23]  M. Vidaud,et al.  The angiopoietin pathway is modulated by PAR‐1 activation on human endothelial progenitor cells , 2006, Journal of thrombosis and haemostasis : JTH.

[24]  Y. Iwasaki,et al.  Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  S. Rafii,et al.  Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Wolf,et al.  CD34+/CD133− circulating endothelial precursor cells (CEP): Characterization, senescence and in vivo application , 2006, Experimental Gerontology.

[27]  C. Perou,et al.  Gene Expression Profile Signatures Indicate a Role for Wnt Signaling in Endothelial Commitment From Embryonic Stem Cells , 2006, Circulation research.

[28]  L. Muller,et al.  PAR-1 Activation on Human Late Endothelial Progenitor Cells Enhances Angiogenesis In Vitro With Upregulation of the SDF-1/CXCR4 System , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[29]  A. Iavarone,et al.  Id2 Mediates Tumor Initiation, Proliferation, and Angiogenesis in Rb Mutant Mice , 2005, Molecular and Cellular Biology.

[30]  B. Peters,et al.  Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.

[31]  K. Pollok,et al.  Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. , 2004, Blood.

[32]  Thierry Couffinhal,et al.  FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway, controls vascular cell proliferation in vitro and in vivo. , 2004, Cardiovascular research.

[33]  Hyun-Jae Kang,et al.  Characterization of Two Types of Endothelial Progenitor Cells and Their Different Contributions to Neovasculogenesis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[34]  Yoshiaki Kawano,et al.  Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.

[35]  Kathleen R. Cho,et al.  Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. , 2003, Cancer research.

[36]  I. Weissman,et al.  Wnt proteins are lipid-modified and can act as stem cell growth factors , 2003, Nature.

[37]  B. Nickoloff,et al.  The Helix–Loop–Helix Protein Id-1 Delays Onset of Replicative Senescence in Human Endothelial Cells , 2002, Laboratory Investigation.

[38]  Jonathan R Pollack,et al.  A transcriptional response to Wnt protein in human embryonic carcinoma cells , 2002, BMC Developmental Biology.

[39]  E. Hara,et al.  Id proteins in cell cycle control and cellular senescence , 2001, Oncogene.

[40]  S. Rafii,et al.  The Id proteins and angiogenesis , 2001, Oncogene.

[41]  I. Bièche,et al.  Quantification of estrogen receptor α and β expression in sporadic breast cancer , 2001, Oncogene.

[42]  A. Nienhuis,et al.  Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  D. Chung,et al.  Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. , 2001, Cancer research.

[44]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[45]  W. Gerald,et al.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.

[46]  I. Bièche,et al.  Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.

[47]  I. Bièche,et al.  Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. , 2001, Oncogene.

[48]  R. Hebbel,et al.  Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.